A Phase II Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer Previously Treated With Standard of Care Chemotherapy (ABC-11)
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs KA 2507 (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- Acronyms ABC-11
- Sponsors Karus Therapeutics
- 30 Jan 2021 Planned initiation date changed from 1 Mar 2020 to 5 Mar 2020.
- 30 Jan 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 31 May 2020 Trial design presented at the 56th Annual Meeting of the American Society of Clinical Oncology